PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34772419-0	2021	PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus.	Nateglinide	95-106	peroxisome proliferator activated receptor delta	Homo sapiens	0-5	
34772419-1	2021	BACKGROUND: Genetic polymorphisms in the PPARD and NOS1AP is associated with type 2 diabetes mellitus (T2DM); however, there is no evidence about its impact on the therapeutic efficacy of nateglinide.	Nateglinide	188-199	peroxisome proliferator activated receptor delta	Homo sapiens	41-46	
34772419-2	2021	This study was designed to investigate a potential association of PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms with efficacy of nateglinide in newly diagnosed Chinese patients with type 2 diabetes mellitus (T2DM).	Nateglinide	147-158	peroxisome proliferator activated receptor delta	Homo sapiens	66-71	
34772419-6	2021	RESULTS: After nateglinide treatment for 8 consecutive weeks, patients with at least one C allele of PPARD rs2016520 showed a smaller decrease in post plasma glucose (PPG), homeostasis model assessment for beta cell function (HOMA-B) than those with the TT genotype did (P < 0.05).	Nateglinide	15-26	peroxisome proliferator activated receptor delta	Homo sapiens	101-106	
34772419-9	2021	CONCLUSIONS: The PPARD rs2016520 and NOS1AP rs12742393 polymorphisms were associated with nateglinide monotherapy efficacy in Chinese patients with newly diagnosed T2DM.	Nateglinide	90-101	peroxisome proliferator activated receptor delta	Homo sapiens	17-22